Literature DB >> 26028048

Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses.

Rita F Santos, Liliana Oliveira, Alexandre M Carmo1.   

Abstract

CD6 immunotherapy to treat psoriasis and rheumatoid arthritis has reached the clinical trial stage with apparent success, and targeting CD6 with mAbs is being used in several animal models of autoimmunity and neuroinflammation with promising indications. However, the mode of action of the therapeutic CD6 mAbs is far from being understood, reflecting the uncertainties and controversy surrounding the mechanistic and biological functions of CD6. Initially regarded as a co-stimulatory receptor of T lymphocytes, recent studies suggest that CD6 can instead modulate early as well as late T cell responses. Also, opposing the contribution of CD6 adhesiveness in the establishment and stabilization of immunological synapses, the actual triggering of CD6 might induce anti-proliferative signals to the T lymphocyte. CD6 has an unusually long cytoplasmic tail and its gene undergoes peculiar patterns of activation-dependent alternative splicing that can on one hand determine whether or not the CD6 protein binds to its ligand, and on the other include or exclude intracellular sequences that may transduce positive or negative signaling. In this review we discuss the multiple aspects that determine the nature of the signals transmitted via CD6 and the context that may define a dual role for this important T cell surface molecule.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26028048     DOI: 10.2174/1389450116666150531152439

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  23 in total

1.  Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis.

Authors:  Mario Martínez-Florensa; Marta Consuegra-Fernández; Fernando Aranda; Noelia Armiger-Borràs; Marianna Di Scala; Esther Carrasco; Jerónimo Pachón; Jordi Vila; Gloria González-Aseguinolaza; Francisco Lozano
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis.

Authors:  Marta Consuegra-Fernández; Marc Julià; Mario Martínez-Florensa; Fernando Aranda; Cristina Català; Noelia Armiger-Borràs; María-Teresa Arias; Francisca Santiago; Antonio Guilabert; Anna Esteve; Carlos Muñoz; Carlos Ferrándiz; José-Manuel Carrascosa; Edurne Pedrosa; Jorge Romaní; Mercè Alsina; José-Manuel Mascaró-Galy; Francisco Lozano
Journal:  Cell Mol Immunol       Date:  2017-12-11       Impact factor: 11.530

3.  The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.

Authors:  P C Rodríguez; D M Prada; E Moreno; L E Aira; C Molinero; A M López; J A Gómez; I M Hernández; J P Martínez; Y Reyes; J M Milera; M V Hernández; R Torres; Y Avila; Y Barrese; C Viada; E Montero; P Hernández
Journal:  Clin Exp Immunol       Date:  2017-11-16       Impact factor: 4.330

4.  Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer.

Authors:  Bangquan Liu; Jiabao Zhai; Wanyu Wang; Tianyu Liu; Chang Liu; Xiaojie Zhu; Qi Wang; Wenjing Tian; Fubin Zhang
Journal:  Front Mol Biosci       Date:  2022-04-19

5.  Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.

Authors:  Marta Consuegra-Fernández; Mario Martínez-Florensa; Fernando Aranda; José de Salort; Noelia Armiger-Borràs; Teresa Lozano; Noelia Casares; Juan José Lasarte; Pablo Engel; Francisco Lozano
Journal:  Front Immunol       Date:  2017-05-30       Impact factor: 7.561

6.  Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses.

Authors:  Esther Carrasco; Cristina Escoda-Ferran; Núria Climent; Cristina Miró-Julià; Inês T Simões; Mario Martínez-Florensa; Adelaida Sarukhan; Esther Carreras; Francisco Lozano
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

7.  Commentary: CD6 As a Potential Target for Treating Multiple Sclerosis.

Authors:  Marta Consuegra-Fernández; Marcos Isamat; Francisco Lozano
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

8.  CD6 modulates thymocyte selection and peripheral T cell homeostasis.

Authors:  Marc Orta-Mascaró; Marta Consuegra-Fernández; Esther Carreras; Romain Roncagalli; Amado Carreras-Sureda; Pilar Alvarez; Laura Girard; Inês Simões; Mario Martínez-Florensa; Fernando Aranda; Ramón Merino; Vanesa-Gabriela Martínez; Rubén Vicente; Jesús Merino; Adelaida Sarukhan; Marie Malissen; Bernard Malissen; Francisco Lozano
Journal:  J Exp Med       Date:  2016-07-04       Impact factor: 14.307

9.  αII-spectrin in T cells is involved in the regulation of cell-cell contact leading to immunological synapse formation?

Authors:  Justyna M Meissner; Aleksander F Sikorski; Tomasz Nawara; Jakub Grzesiak; Krzysztof Marycz; Dżamila M Bogusławska; Izabela Michalczyk; Marie-Christine Lecomte; Beata Machnicka
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

10.  T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.

Authors:  Usha Bughani; Arindam Saha; Anshu Kuriakose; Reshmi Nair; Ravindra B Sadashivarao; Rasika Venkataraman; Swati Patel; Anuja Tushar Deshchougule; Satish Kumar S; Enrique Montero; Harish V Pai; Dinesh V Palanivelu; Ramakrishnan Melarkode; Pradip Nair
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.